ArticleDrugs - real world outcomes2026
Treatment Patterns and Healthcare-Related Costs in Patients with Atherosclerotic Cardiovascular Disease: Insights from a Large US Healthcare Insurer.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAtherosclerotic cardiovascular disease (ASCVD) is a leading cause of death in the USA. We evaluated lipid-lowering therapy (LLT) and the impact of adherence on healthcare costs among patients with ASCVD.
methodsThis observational cohort study used payor claims and outpatient laboratory data. Adults with ASCVD diagnosed from 1 October 2015 to 31 December 2019 were observed 12 months before, and up to 24 months after, first LLT use (index; categorized as any LLT, statin monotherapy, ezetimibe monotherapy, or anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibody [PCSK9 mAb] monotherapy). Treatment patterns, low-density lipoprotein cholesterol (LDL-C) measurements, LLT adherence (proportion of days covered ≥ 0.80), and healthcare resource utilization and costs were reported.
resultsOf patients with 12 months' follow-up post-ASCVD diagnosis, 35% did not receive LLT within 12 months. Among those receiving any LLT, 95.4% received statin monotherapy at index, 1.6% ezetimibe monotherapy, and 0.3% anti-PCSK9 mAb monotherapy. In the cohort with 12 months' follow-up post-index (N = 417,625), the proportion of adherent patients was 66.0% for statin monotherapy, 58.0% for ezetimibe, and 54.9% for anti-PCSK9 mAb users. Among adherent patients, 25.0% of statin, 13.5% of ezetimibe, and 37.7% of anti-PCSK9 mAb users achieved LDL-C < 70 mg/dL within 12 months. ASCVD-related 12-month per patient per month medical costs were higher for nonadherent patients across LLT categories except ezetimibe.
conclusionsThe high proportion of patients not reaching their LDL-C goal, including those adherent to LLT, demonstrates persistent gaps in care. Adherent patients had lower LDL-C and lower ASCVD-related costs.
Identifiers
42295641What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.